Journal profile · Peripheral Vascular Disease
Clinical and Applied Thrombosis/Hemostasis
ISSN 1076-0296 · eISSN 1938-2723 · SAGE Publications Inc. · UNITED STATES · Quarterly · Founded 1995
Clinical and Applied Thrombosis/Hemostasis: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.05; fully open access; APC about USD 2,650; review about 2 months (community reports); community-reported acceptance: about 50%; 154 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical and Applied Thrombosis/Hemostasis is published by SAGE Publications Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Venous Thromboembolism Diagnosis and Management, Blood Coagulation and Thrombosis Mechanisms and Atrial Fibrillation Management and Outcomes, together about 43.1% of its articles. Its main subfields are Hematology and Cardiology and Cardiovascular Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Clinical and Applied Thrombosis/Hemostasis (CATH) is a peer-reviewed open access journal which focuses on the practical clinical and laboratory issues involved in managing bleeding and clotting disorders, especially those related to thrombosis, hemostasis, and … | View full journal description This journal is a member of the Committee on Publication Ethics (COPE).
From the journal's Aims & Scope
Research area (LetPub): Peripheral Vascular Disease
Editorial board by country: 5 in mainland China (about 6%); most named United States 29, Mainland China 5, Germany 5, Canada 5, Türkiye 5 (79 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Venous Thromboembolism Diagnosis and ManagementMedicine21.4%
- Blood Coagulation and Thrombosis MechanismsMedicine11.9%
- Atrial Fibrillation Management and OutcomesMedicine9.7%
- Platelet Disorders and TreatmentsMedicine7.1%
- Heparin-Induced Thrombocytopenia and ThrombosisMedicine5%
- Acute Myocardial Infarction ResearchMedicine4.5%
- Antiplatelet Therapy and Cardiovascular DiseasesMedicine4.4%
- Hemophilia Treatment and ResearchMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Peripheral Vascular Disease | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
| Minor | Peripheral Vascular Disease | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.05LetPub ·
- Impact factor (publisher)
- 2.1Publisher website ·
- 5-year impact factor (publisher)
- 2.3Publisher website ·
- CiteScore 2026-06
- 3.8LetPub ·
- SJR 2026-06
- 0.67LetPub ·
- SNIP 2026-06
- 0.81LetPub ·
- h-index
- 48LetPub ·
- h-index
- 77OpenAlex ·
- i10-index
- 1,586OpenAlex ·
- 2-year mean citedness
- 1.74OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 99.78%LetPub ·
Volume
- Articles per year
- 151LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
Articles by year OpenAlex count · 3,537 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 173 | 173 | 35 |
| 2025 | 154 | 154 | 227 |
| 2024 | 139 | 139 | 547 |
| 2023 | 167 | 167 | 1,224 |
| 2022 | 182 | 182 | 1,902 |
| 2021 | 187 | 187 | 2,838 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Acceptance rate (publisher)
- 43.2%Publisher website ·
- Submission to first decision
- 5 daysPublisher website ·
- Acceptance to publication
- 18 daysPublisher website ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,650 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,650 | — | — | |
| LetPub | USD 3,000 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- SAGE Publications Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 1995
- ISSN
- 1076-0296
- Electronic ISSN
- 1938-2723
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical and Applied Thrombosis/Hemostasis
What CAS zone is Clinical and Applied Thrombosis/Hemostasis in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical and Applied Thrombosis/Hemostasis is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology / Peripheral Vascular Disease. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical and Applied Thrombosis/Hemostasis?
The latest impact factor listed by LetPub is 2.05; CiteScore 3.8, h-index 77.
How long does peer review take at Clinical and Applied Thrombosis/Hemostasis?
Authors report an average review time of about 2 months; the community-reported acceptance is “about 50%”; the journal's website gives an acceptance rate of 43.2%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Clinical and Applied Thrombosis/Hemostasis based?
Of the 79 board members whose country the journal's board page names, 5 (about 6%) are in mainland China; the countries named most often are United States (29), Mainland China (5) and Germany (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical and Applied Thrombosis/Hemostasis?
According to LetPub and DOAJ records, Clinical and Applied Thrombosis/Hemostasis is indexed in SCIE, Scopus and DOAJ.
Is Clinical and Applied Thrombosis/Hemostasis open access, and what is the APC?
Clinical and Applied Thrombosis/Hemostasis is a fully open-access journal. APC about USD 2,650.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .